The Latest

The fast-growing shockwave market is already valued at $3 billion. Manufacturers around the world are investing in new devices and applicators to address the rising demand for non-surgical therapeutic options. They need clinical evidence to support those new technologies. Increasingly, that evidence will not come from clinical trials, but your everyday clinical data and outcomes.Physicians-Owned Circles (POCs) streamline the capture, aggregation and licensure of high-quality, real-world shockwave data. Qualifying Principal Investigators receive 10% of resulting license fees, and qualifying Investigators share 75%. Cost and time obligations are minimal, and the data is yours to use for various non-commercial purposes.

On November 12, RegenMed’s CEO and Co-Founder Michael P. Tierney conducted a webinar discussing the Company’s investment theses and global traction. The webinar recording has been divided into ten chapters, now available on the Company’s Investors Page.On Monday, December 16, the Company will host its “Expectations 2025” webinar for current and potential investors. Mr. Tierney will review continuing traction and growth expected through the end of the year. He will also discuss the strong buy-in from North American and European clients of its recently launched Physicians-Owned Circles, and the implications of POCs for forecasted 2025 revenues. Adequate time will be left to address questions. This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Investors presentations may contain forward-looking statements based on current expectations. Actual results could differ significantly due to various risks and uncertainties.

Please join us for RegenMed, Inc. Investors Webinar, Monday, December 16 at 6:30 PM, New York time .RegenMed's CEO Michael P Tierney will review the Company's momentum through the end of the year, as well as expectations for 2025.For more information, see our Investors Page.

RegenMed Webinar: Michael P. Tierney, CEO and Co-Founder, Discusses The Company’s Investment Theses RegenMed is an established, revenue-producing company disrupting a + $1 trillion healthcare data market. Our November 12 webinar discussed the foundational elements which have led to its global client base, strong monthly recurring revenue growth, competitive moats, and plans for accelerated market capture. A total of ten self-contained segments from that webinar can be viewed on the Company’s Investors Page. The first three can be viewed below. The remainder will be published in subsequent Campaign Updates. THE FOUNDING OF A “ZERO-TO- ONE” COMPANY REAL WORLD HEALTHCARE DATA: THE RAW MATERIAL OF A + $1 TRILLION MARKET THE VALUABLE FINAL PRODUCT: REAL-WORLD EVIDENCE Invest today in a company with a proven product market fit, growing recurring revenues, competitive moats, and seasoned leadership which is disrupting a + $1 trillion market.

RegenMed was founded – and operates – on a fundamental financial principle: the most valuable company is that which can establish and then grow recurring revenues across a diverse client base. It is thus distinctive from many other forms of healthcare investments.The Challenges For Pre-Revenue Healthcare CompaniesHealthcare is obviously an enormous market – in the United States alone, it represents fully 17% of the country’s GDP. 1There are therefore thousands of investment opportunities, both with established and newer companies. Many of the latter tend to be bets on new products with any revenues far into the future. While some of these bets pay off, the great majority do not.Unfortunately, it is very difficult even for the largest drug companies to predict which of their clinical trials will prove successful. On average, 14% of drugs and vaccines that enter clinical trials receive regulatory approval. (Only 2% for oncology drugs.)The Financial ConsequencesOnly the best capitalized companies can withstand the financial implications of this reality. In 2023, biotech bankruptcies reached a 10-year high, with more companies filing for bankruptcy than any year since 2010. This trend continued into 2024, with 22 biotech companies shutting down. 2 Indeed, the broader healthcare industry also saw a surge in bankruptcies. In 2023, 79 healthcare companies with liabilities of at least $10 million filed for bankruptcy, more than triple the number in 2021. 3 In 2023, 17 out of 80 healthcare bankruptcies (21%) involved private equity-backed firms, marking a 112.5% increase over the past five years. 4How RegenMed Is DifferentRegenMed is selling shovels to gold miners – its patented product Circles is needed by any medical provider or product manufacturer which needs to conduct a clinical study. (As discussed in an earlier post, RegenMed also participates with its clients in the monetization of those studies.) RegenMed has established a strong product-market fit, with revenues earned from a broad variety of clients in North America, Europe and elsewhere. Those revenues are recurring and growing – the company’s business model is predicated on monthly subscriptions and small per Case charges. This low pricing is an important competitive moat in today’s far-too-expensive healthcare world. It also allows rapid scaling. RegenMed is led by an experienced management team with proven track records. They know that “slow and steady” wins the race. They focus on cash earnings, minimizing debt, and continuing to scale the Company’s established product-market fit in its large addressable markets.